Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Urology, University of California San Francisco, San Francisco, CA, USA.
Eur Urol Focus. 2018 Sep;4(5):720-724. doi: 10.1016/j.euf.2016.12.005. Epub 2017 Jan 18.
For patients with bladder cancer (BC) receiving neoadjuvant chemotherapy (NAC), complete pathologic absence of tumor (pT0) at radical cystectomy (RC) is associated with better survival. It is unclear if pT0 status can be attributed to the absence of residual disease (cT0) on transurethral resection of bladder tumor (TURBT) or to the effects of NAC.
To determine how often cT0 is associated with pT0 and identify preoperative and postoperative factors associated with survival.
DESIGN, SETTING, AND PARTICIPANTS: Between 1995 and 2011, 157 out of 1897 RC patients were identified as stage cT0 after at least two TURBT procedures at a single center.
RC with or without NAC.
Initial TURBT pathology and clinical staging were reviewed. The primary endpoint was pathologic stage at RC. Cox proportional hazards ratios identified factors associated with residual disease at RC, overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS).
Of the cT0 patients, 49.7% (n=78) underwent NAC. pT0 was found in 35.7% (n=56). Residual tumor was found at RC in 63.7% (n=101), of whom 24.8% (n=39) had advanced disease (≥pT3 or node-positive disease). Positive lymph nodes at RC were found in 12.7% (n=20) of the patients. There was no significant difference in achieving pT0 status between patients with and without NAC. The presence of advanced BC was most predictive of OS. NAC was associated with longer OS and RFS. During median follow-up of 6.3 yr, the 5-yr RFS was 81% for those with non-advanced disease and 46% for advanced BC (p<0.001). The 5-yr OS rate was 77% for non-advanced BC and 46% for invasive BC (p<0.001). Limitations include the retrospective design.
Complete TURBT does not predict pT0 at RC. A notable fraction of patients with cT0 bladders have locally advanced and/or lymph node-positive disease. These findings may be of value when counseling patients on bladder preservation strategies for muscle-invasive BC.
Among patients thought to have had the entire tumor in their bladder removed via cystoscopy, a majority have persistent tumors when their bladders were removed. In a sizable proportion, these persistent tumors were even more invasive than initially thought.
对于接受新辅助化疗(NAC)的膀胱癌(BC)患者,根治性膀胱切除术(RC)时完全病理无肿瘤(pT0)与更好的生存相关。目前尚不清楚 pT0 状态是归因于经尿道膀胱肿瘤切除术(TURBT)时无残留肿瘤(cT0),还是归因于 NAC 的作用。
确定 cT0 与 pT0 相关的频率,并确定与生存相关的术前和术后因素。
设计、设置和参与者:在单个中心,1995 年至 2011 年间,在至少两次 TURBT 后,1897 例 RC 患者中有 157 例被确定为 cT0 期。
RC 联合或不联合 NAC。
回顾初始 TURBT 病理和临床分期。主要终点是 RC 的病理分期。Cox 比例风险比确定了与 RC 时残留疾病、总生存(OS)、无复发生存(RFS)和疾病特异性生存(DSS)相关的因素。
在 cT0 患者中,49.7%(n=78)接受了 NAC。pT0 见于 35.7%(n=56)。63.7%(n=101)的患者在 RC 时发现有残留肿瘤,其中 24.8%(n=39)患有晚期疾病(≥pT3 或淋巴结阳性疾病)。RC 时发现阳性淋巴结的患者占 12.7%(n=20)。接受 NAC 和未接受 NAC 的患者在达到 pT0 状态方面无显著差异。晚期 BC 的存在是 OS 的最主要预测因素。NAC 与更长的 OS 和 RFS 相关。在中位随访 6.3 年期间,非晚期疾病患者的 5 年 RFS 为 81%,而晚期 BC 患者为 46%(p<0.001)。非晚期 BC 的 5 年 OS 率为 77%,而浸润性 BC 为 46%(p<0.001)。局限性包括回顾性设计。
完全 TURBT 并不能预测 RC 时的 pT0。相当一部分 cT0 膀胱患者的肿瘤局部进展和/或淋巴结阳性。这些发现可能在为肌层浸润性 BC 患者提供膀胱保留策略咨询时具有价值。
在那些认为通过膀胱镜已经切除了膀胱内全部肿瘤的患者中,大多数患者在切除膀胱时仍有肿瘤残留。在相当大的一部分患者中,这些残留肿瘤甚至比最初认为的更具侵袭性。